Open AccessBevacizumab in Treatment of High‐Risk Ovarian Cancer—A Cost‐Effectiveness Analysis
Author(s) -
Chan John K.,
Herzog Thomas J.,
Hu Lilian,
Monk Bradley J.,
Kiet Tuyen,
Blansit Kevin,
Kapp Daniel S.,
Yu Xinhua
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2013-0322
Subject(s) - medicine , bevacizumab , ovarian cancer , carboplatin , oncology , paclitaxel , stage (stratigraphy) , cancer , chemotherapy , cisplatin , paleontology , biology
Objective. The objective of this study was to evaluate a cost‐effectiveness strategy of bevacizumab in a subset of high‐risk advanced ovarian cancer patients with survival benefit. Methods. A subset analysis of the International Collaboration on Ovarian Neoplasms 7 trial showed that additions of bevacizumab (B) and maintenance bevacizumab (mB) to paclitaxel (P) and carboplatin (C) improved the overall survival (OS) of high‐risk advanced cancer patients. Actual and estimated costs of treatment were determined from Medicare payment. Incremental cost‐effectiveness ratio per life‐year saved was established. Results. The estimated cost of PC is $535 per cycle; PCB + mB (7.5 mg/kg) is $3,760 per cycle for the first 6 cycles and then $3,225 per cycle for 12 mB cycles. Of 465 high‐risk stage IIIC (>1 cm residual) or stage IV patients, the previously reported OS after PC was 28.8 months versus 36.6 months in those who underwent PCB + mB. With an estimated 8‐month improvement in OS, the incremental cost‐effectiveness ratio of B was $167,771 per life‐year saved. Conclusion. In this clinically relevant subset of women with high‐risk advanced ovarian cancer with overall survival benefit after bevacizumab, our economic model suggests that the incremental cost of bevacizumab was approximately $170,000.